Cholesterol-lowering drugs for high-risk hypercholesterolemia patients with COVID-19 while on Paxlovid™ therapy

Area of Science:

• Pharmacology and Cardiovascular Medicine

Background:

• Paxlovid (nirmatrelvir/ritonavir) is an oral antiviral treatment for COVID-19 in high-risk individuals.
• Hypercholesterolemia, particularly severe forms like heterozygous familial hypercholesterolemia, increases cardiovascular event risk.
• Concomitant use of Paxlovid and statins poses a significant drug interaction risk due to CYP3A metabolism.

Purpose of the Study:

• To address the critical need for managing statin therapy during Paxlovid treatment in COVID-19 patients with hypercholesterolemia.
• To provide guidance on statin management to prevent adverse cardiovascular events during Paxlovid administration.

Main Methods:

• Review of pharmacokinetic interactions between Paxlovid and statins, focusing on cytochrome P450 3A (CYP3A) pathways.
• Analysis of the clinical implications of abrupt statin withdrawal and the necessity of continuous lipid-lowering therapy.
• Formulation of recommendations for statin substitution or dose adjustment during the 5-day Paxlovid treatment course.

Main Results:

• Paxlovid co-administration with CYP3A-metabolized statins (e.g., simvastatin, lovastatin) can lead to potentially harmful drug interactions.
• Discontinuation of statin therapy during Paxlovid treatment may precipitate serious negative cardiovascular rebound effects.
• Specific statin management strategies are required, including substitution with less interacting statins (pravastatin, fluvastatin) or dose reduction (atorvastatin, rosuvastatin).

Conclusions:

• Continuous statin therapy is essential for patients with hypercholesterolemia undergoing Paxlovid treatment.
• Careful selection and dosing of statins are crucial to mitigate drug interactions and prevent cardiovascular complications.
• This guidance supports safe and effective management of co-existing conditions during acute COVID-19 treatment.